Document Detail


Sequential outpatient application of intravaginal prostaglandin E2 gel in the management of postdates pregnancies.
MedLine Citation:
PMID:  2047061     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A randomized blinded investigation was undertaken to determine the efficacy and safety of sequentially applied intravaginal prostaglandin E2 (PGE2) gel for accelerating cervical ripening in an outpatient setting in low-risk prolonged pregnancies. Fifty women with uncomplicated pregnancies at or beyond 41 weeks' gestation and Bishop scores below 9 received twice-weekly outpatient administration of gel containing 2.0 mg of PGE2 or placebo. Thirty nulliparas and 20 multiparas were enrolled. The PGE2 gel failed to improve cervical ripening over placebo, as judged by Bishop scores. There was no difference between the groups in gestational age on admission to the labor and delivery suite, number of gel applications, requirement for oxytocin, incidence of cesarean delivery, or neonatal outcome. Only two patients (4%) experienced regular uterine contractions after gel insertion; these subsided spontaneously in both. None of the subjects experienced labor, tetanic contractions, evidence of fetal distress, or any other side effects related to gel insertion. We conclude that PGE2 gel in this dosage may be used safely in an outpatient setting, but more frequent application or earlier initiation may be required to produce a clinical effect.
Authors:
S K Sawai; M C Williams; W F O'Brien; J L Angel; D S Mastrogiannis; L Johnson
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  78     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1991 Jul 
Date Detail:
Created Date:  1991-07-16     Completed Date:  1991-07-16     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  19-23     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravaginal
Ambulatory Care
Cervix Uteri / drug effects
Dinoprostone / administration & dosage,  adverse effects,  therapeutic use*
Double-Blind Method
Female
Gels
Humans
Labor, Induced / methods*
Oxytocin / therapeutic use
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy, Prolonged / drug effects*
Time Factors
Chemical
Reg. No./Substance:
0/Gels; 363-24-6/Dinoprostone; 50-56-6/Oxytocin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Peripheral pulse pressure patterns in pregnancy hypertension.
Next Document:  Tensile strength and collagen content of amniotic membrane do not change after the second trimester ...